Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Bought by Trexquant Investment LP

Trexquant Investment LP raised its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 47.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 128,606 shares of the company's stock after purchasing an additional 41,147 shares during the quarter. Trexquant Investment LP owned about 0.42% of Fulgent Genetics worth $2,375,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in FLGT. Headlands Technologies LLC acquired a new position in Fulgent Genetics in the fourth quarter valued at $120,000. Geode Capital Management LLC raised its holdings in shares of Fulgent Genetics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 514,152 shares of the company's stock worth $9,499,000 after purchasing an additional 11,283 shares during the period. Diametric Capital LP acquired a new position in shares of Fulgent Genetics in the 4th quarter valued at about $717,000. JPMorgan Chase & Co. grew its holdings in shares of Fulgent Genetics by 39.4% during the 4th quarter. JPMorgan Chase & Co. now owns 471,259 shares of the company's stock worth $8,704,000 after purchasing an additional 133,215 shares during the period. Finally, EntryPoint Capital LLC increased its position in Fulgent Genetics by 85.2% during the 4th quarter. EntryPoint Capital LLC now owns 20,771 shares of the company's stock worth $384,000 after purchasing an additional 9,556 shares in the last quarter. 48.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Paul Kim purchased 100,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were purchased at an average price of $15.96 per share, with a total value of $1,596,000.00. Following the purchase, the chief financial officer now directly owns 348,282 shares of the company's stock, valued at approximately $5,558,580.72. This represents a 40.28 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 31.76% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

FLGT has been the topic of a number of recent research reports. StockNews.com raised shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a research report on Wednesday, March 5th. Piper Sandler reduced their target price on shares of Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th.

Fulgent Genetics Stock Up 9.6 %

Shares of NASDAQ FLGT traded up $1.67 on Friday, hitting $19.00. The company had a trading volume of 413,823 shares, compared to its average volume of 255,116. The firm has a market capitalization of $586.45 million, a P/E ratio of -3.44 and a beta of 1.36. Fulgent Genetics, Inc. has a 12-month low of $14.57 and a 12-month high of $25.11. The business has a 50 day moving average of $16.91 and a two-hundred day moving average of $18.30.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.